Welcome to HitGen

News

Get up to date with the latest HitGen articles and join us in the events

Press Release

  • 23 December 2021
    Lipigon and HitGen extend collaboration agreement on dyslipidemia project
  • 05 November 2021
    HitGen and Cambridge Molecular announce a strategic partnership, bringing together DNA-Encoded Libraries and Deep Learning
  • 01 November 2021
    Vernalis Research - a fully owned subsidiary of HitGen Inc - and Hannibal Innovation announce the creation of Dania Therapeutics ApS
  • 29 October 2021
    Infographic|HitGen FY2021 Q3 Report
  • 02 September 2021
    Veritas In Silico and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based RNA-targeting small molecule Drug Discovery
  • 31 August 2021
    Infographic | HitGen FY2021 Mid-term Report
Read More

Coverage

  • July 15, 2020

    Jin LI – Chairman & CEO, HitGen, China

    PHARMA BOARDROOM Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early drug discovery, and the next steps for the company’s expansion. "By now, we have a platform of over 500 billion small molecules, and in terms of published numbers, we probably have the largest DEL collections in the world. By the end of this year, we hope to have built a DEL of over one trillion small molecules!"
  • May 07, 2020

    New economy business becomes a growing driver of city development

    China Daily, Yuan Shenggao 2020-05-07 HitGen, a local biopharmaceutical company, was listed on the science and technology innovation board at the Shanghai Stock Exchange in mid-April, and is the first company in southwestern China to appear on the board. The company, founded in 2012, provides research services for the early stages of drug discovery using its core DNA encoded compound library technology. It has established partnerships with multinational drug and biomedicine companies such as Pfizer, Johnson & Johnson, MSD and Sanofi. Li Jin, chairman and general manager of HitGen, said it will expand investment into DNA encoded compound library technology and business, to promote research and development of drugs.
  • April 29, 2020

    Chinese biotech firm uses DNA to discover new drugs

    CGTN, By Wei Lynn Tang HitGen Inc., a Chengdu-based biotechnology company that has listed on China's Science and Technology Innovation Board on April 16, raising some 118 million U.S. dollars. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project. Li Jin, chairman and CEO of HitGen, said the company's top priority is to continue to invest in its core technology – the DEL technology – to make progress in its drug discovery programs.
Read More

Events

January 12-01
Meet you in JPM 2022
June 30-30
Webinar: Advancing Innovative Drug Discovery by DNA Encoded Library (DEL) and FBDD/SBDD methods
June 09-21
BIO KOREA 2021
May 10-14
ChinaBio
January 11-01
Meet us in BIOTECH SHOWCASE™2022 in virtual!
June 10-18
BIO International Digital Convention 2021
May 18-20
Drug Discovery Chemistry
Read More

Industry News

  • 12.04
    Richard Lerner Remembrance
    It is with great sadness that we hear of the passing of Professor Richard A Lerner. Richard served as the director of the Scripps Research Institute from 1991 until 2012, and in 1992 published the seminal paper in PNAS describing the concept of recording a series of chemical transformations by a DNA “code” with his Scripps colleague and Nobel laureate Dr. Sidney Brenner (1927-2019).
  • 12.29
    Exploring Aldol Reactions on DNA and Applications to Produce Diverse Structures: An Example of Expanding Chemical Space of DNA-Encoded Compounds by Diversity-Oriented Synthesis.
    Chem. Asian J. 2020, 15, 4033 https://doi.org/10.1002/asia.202001105
  • 12.03
    A Method for Estimating Binding Affinity From Primary DEL Selection Data
    Biochemical and Biophysical Research Communications Volume 533, Issue 2 DOI: 10.1101/2020.05.04.077842
  • 08.01
    A B2(OH)4-Mediated Synthesis of 2-Substituted Indazolone and Its Application in a DNA-Encoded Library
    Org. Lett. 2020, 22, 16, 6277–6282 https://doi.org/10.1021/acs.orglett.0c02032
Read More

Questions?

For more details on how we can advance your innovative drug discovery projects
By submitting your information, you acknowledge having received, read and understood our Privacy Notice as made available above.

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information